Jay Harper
Director, Oncology Targeted Discovery AstraZeneca
Seminars
In an ever-growing clinical landscape and with the threat of patient resistance, the role of combinations is crucial to bring better ADC treatments to oncology patients.
Join this long-standing seminar day for an overview of ADC clinical combination leaders, assess applications of dual payload ADCs to tackle payload resistance, and delve into rationale-driven practices to smartly select and investigate the right ADC combination partners
Download the Full Event Guide for full details
Rejoin your ADC combination speakers and attendees after lunch for a closing panel discussion to discuss, debate and evaluate the opportunities and challenges in combination clinical performance, optimising partner selection, the
power of ADC sequencing and dual payload conjugates, and more. Make sure to come with your thoughts and questions prepared!
Discussion Highlights Include:
- Explore the impact of ADC combination on the oncology treatment landscape: Will combination therapies become the norm as ADCs progress to earlier-line patient therapies?
- Understanding the best rationale to smartly select appropriate ADC combination partners
- Evaluating the ability of ADC sequencing and dual payload combinations to combat resistance to payloads
- Optimizing strategy for ADC combination trials
- Overviewing exciting ADC combination data generated in 2025
- Looking to the future: what are the next steps for progressing ADC combinations?
